Brief: Ocugen Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
10/11/2023 12:32
Nov 10 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
CLINICAL
TRIAL EVALUATING THE SAFETY AND EFFICACY OF OCU410ST—MODIFIER
GENE THERAPY—FOR STARGARDT DISEASE
Source text for Eikon: ID:nGNX9fHHm
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))